Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

John Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About ‘Big Pharma’

lab_tech02

This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big myths about big pharma in this Forbes opinion piece. He points to these five biggest industry myths as ‘routinely poisoning debates, obscuring genuine problems, and distorting policy recommendations on health care.’ In short (excerpts): Myth #1 Pharmaceutical companies exaggerate the costs of developing new medicines to justify high prices. In fact: The research and development (R&D) expenditures of this industry Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Applauds Energy and Commerce Health Subcommittee for Approving 21st Century Cures Act

21st-Century-Cures--Free

Today, the Biotechnology Industry Organization (BIO) praises the Energy and Commerce Health Subcommittee for approving and forwarding to the full Committee the 21st Century Cures Act. We applaud the Energy and Commerce Committee for recognizing the critical link between research, development, and reimbursement. We look forward to continuing to work with Chairman Fred Upton (R-MI), Congresswoman Diana DeGette (D-CO), and members of the Energy and Commerce Committee to help expedite the delivery of the next Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Tick Size Pilot Program: A Few Pennies Make a Big Difference

72263479

Earlier this week, the Securities and Exchange Commission (SEC) approved a tick size pilot program that will begin next year. We issued this statement, praising the SEC for finalizing this program, which could improve liquidity and enhance capital formation for emerging biotech companies. Under current SEC rules, all securities on the public market are priced in $0.01 increments known as “tick sizes.” The switch to the standard tick size of a penny was enacted in 2000 Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

United Health To Congress: Let Cancer Patients Eat Gauze (Op-Ed in The Hill)

Patient

Jonathan Wilcox’s op-ed in The Hill today highlights the growing challenge of insurance company tactics that contribute to increased costs to the health care system and restricted patient access to life-saving medicines. While UnitedHealth Group just reported increased revenues for first quarter 2015, patients are shouldering the burden with rising copays and restricted coverage, asserts the author. As Wilcox writes, ‘That’s why cancer advocacy organizations are taking action, pressing Congress and state legislatures to cap co-pays on specialty Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Principles on Expanded Access to Investigational, Unapproved Medicines

lab_tech

Seriously ill patients with limited or no alternative therapies, and who are ineligible or unable to participate in the clinical trials, may desire access to investigational, unapproved medicines.  Such access outside of the clinical trial setting, or “expanded access,” may be sought through a company’s expanded access program, or through individual patient expanded access, if available. We believe that the best way to make innovative biotechnology medicines available to patients is through the efficient development of approved, safe Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,